GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Current Ratio

Bolt Biotherapeutics (Bolt Biotherapeutics) Current Ratio : 5.68 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bolt Biotherapeutics's current ratio for the quarter that ended in Mar. 2024 was 5.68.

Bolt Biotherapeutics has a current ratio of 5.68. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Bolt Biotherapeutics's Current Ratio or its related term are showing as below:

BOLT' s Current Ratio Range Over the Past 10 Years
Min: 2.25   Med: 7.42   Max: 22.58
Current: 5.68

During the past 6 years, Bolt Biotherapeutics's highest Current Ratio was 22.58. The lowest was 2.25. And the median was 7.42.

BOLT's Current Ratio is ranked better than
64.43% of 1552 companies
in the Biotechnology industry
Industry Median: 3.775 vs BOLT: 5.68

Bolt Biotherapeutics Current Ratio Historical Data

The historical data trend for Bolt Biotherapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Current Ratio Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 4.15 2.25 8.87 7.47 5.17

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.10 7.42 6.69 5.17 5.68

Competitive Comparison of Bolt Biotherapeutics's Current Ratio

For the Biotechnology subindustry, Bolt Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Current Ratio falls into.



Bolt Biotherapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Bolt Biotherapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=105.708/20.456
=5.17

Bolt Biotherapeutics's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=95.055/16.723
=5.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (NAS:BOLT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Bolt Biotherapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at February Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023